Navigation Links
Vantia Therapeutics' Pipeline Continues to Mature
Date:3/24/2009

argeted therapy.

There has also been progress in Vantia Therapeutics' preclinical portfolio. The lead indications for the kallikrein inhibitor candidate VA118020, which moved into preclinical development at the end of last year, will be asthma and COPD. Clinical trials are expected to start in 2010. The company has also initiated a new programme involving an oral plasma kallikrein inhibitor which may have potential in the treatment of hereditary angioedema (HAE). HAE, which is thought to affect up to 15,000 people world wide, is characterised by episodes of swelling in various parts of the body including the airways. It can lead to pain, nausea, vomiting and death by asphyxiation, and an oral treatment would be expected to provide advantages over existing therapies.

Dr Jim Phillips, CEO of Vantia Therapeutics, said, 'Vantia is pleased to report that its two lead drug candidates continue to make clinical progress, and is looking forward to the trial results. As the next development steps proceed we will be engaging with potential partners for these products. In addition, our preclinical progress emphasises the ability of Vantia's small molecule library to populate our pipeline and our expertise in this area.'

Notes to Editors

About Vantia Therapeutics:

Vantia Therapeutics is a UK-based R&D company focused on first-in-class therapies for recognised markets which are underserved by current therapies. Formed in 2008 as a spin-out of Ferring Research Ltd's small molecule R&D, it has two clinical phase products, VA106483 for the treatment of nocturia in BPH patients and VA111913 for the treatment of dysmenorrhoea, as well as preclinical and discovery programmes based on protease inhibition with potential in the areas of oncology and inflammation. The company's investors include MVM Life Science Partners, SV Life Sciences and Novo A/S. Vantia Therapeutics is situated on Sou
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 /CNW/ - Atlantic Canadians will save an ... Canada,s provinces and territories and ... of the Canadian Generic Pharmaceutical Association (CGPA), said today. ... speaking at the Atlantic Summit on Healthcare and Drug ... is being hosted by the Public Policy Forum and ...
(Date:10/30/2014)... 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology, and medical device ... and the United States , today ... Tel Aviv area of Israel.  ... broad platform of integrated R&D services to local customers. ...
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
Breaking Medicine Technology:Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 3WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
... , SCHAUMBERG, Ill., Nov. 19 ... of flexible, PACS-neutral healthcare image management solutions, and QStar ... PACS- neutral archive solution through their common US distribution ... image distribution and archiving solutions to the medical industry. ...
... Care Doctors, Endocrinologists Feel Ill-Equipped to Provide Ideal, Multi-Disciplinary Team ... of doctors surveyed said they did not have enough time ... to their patients with diabetes, according to the results of ... in American Health & Drug Benefits . , An ...
Cached Medicine Technology:Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 2Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 3Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 4Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 2Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 3Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 4Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 5
(Date:10/31/2014)... — A team from the Broad Institute, the ... California, Santa Cruz, was awarded one of three ... contracts with the goal of building a system ... Genome Atlas (TCGA) and other datasets by co-locating ... one cloud environment. This co-location will enable researchers ...
(Date:10/31/2014)... October 31, 2014 At the start ... families narrowly escaping carbon monoxide poisoning in their homes. ... weeks away, one family-owned, Missouri-based heating and cooling company ... making sure families start the home heating season with ... secure. , Beginning Nov. 1, 2014, E and ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Sleep apnea may make ... where you parked your car or left your house keys, ... severe sleep apnea showed that this ability -- called spatial ... movement (REM) sleep, even when other stages of sleep weren,t ... which dreams typically occur. "We,ve shown for the first ...
(Date:10/31/2014)... a lab device to give cancer researchers an unprecedented ... cells spread through the body, causing more than 90 ... how tumor cells travel, the device could uncover new ... from the university,s Whiting School of Engineering and its ... their new system recently in the journal Cancer ...
(Date:10/31/2014)... combination that can trigger the self-destruct process in lung ... according to research that will be presented at the ... next week*. , When healthy cells are no longer ... self destruction. But cancer cells swerve away from this ... grow out of control – causing tumours to form. ...
Breaking Medicine News(10 mins):Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 2Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 3Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... have found that an active lifestyle with limiting TV time ... conducted in the US TV watching results in a lower ... games, reading, writing or driving a car. Prolonged TV watching ... are focussed on increasing exercise and hardly concentrate on reducing ...
... whether daily moderate exercise could actually prevent Heart disease. ... hiking, climbing stairs, racket sports and swimming does really ... disease. Recommendations in the United States and elsewhere say ... sufficient for good heart health.// A World Health Organization ...
... that mice lacking a specific immune cell are unable to ... (AHR) which is narrowing of the tiny passages in the ... mite. AHR is triggered by the immune system and leads ... attack. Researchers at Stanford University have been studying mice that ...
... health of their children most expecting moms will do whatever needs ... of rest. But are those moms who smoke, ready to set ... moms willing to put their habit on ,hold for the sake ... recent meeting of the Baxter County Tobacco Control Committee was ,that// ...
... particularly those who are breastfed, should be given vitamin D ... the bones fail to grow straight and strong. While breast ... contain enough vitamin D to meet babies needs. This happens ... of the vitamin D. All infant formula sold in the ...
... now studied a new electrical device,that might lead ... Parkinson's disease.,This new treatment involves implanting an electrical ... for Parkinson's patients. This,electrical device helps stimulate both ... otherwise cause disabling tremor. The researchers ran a ...
Cached Medicine News:
... Rapid Plasma Reagin ... rapid detection and quantitative ... serum or plasma. Uses ... to detect reagin. Kits ...
Latex agglutination slide test for the qualitative and semi-qualitative detection of antinuclear antibodies to aid in the diagnosis of systemic lupus erthyematosus....
... Rapid Plasma Reagin card ... detection and quantitative determination ... or plasma. Uses carbon ... detect reagin. Kits include ...
Test for the quantitative determination of antideoxyribonuclease-B (ADNase-B) in serum....
Medicine Products: